Leprosy elimination drive intensifies as Indian govt pushes high-burden states toward zero transmission goal

Patnaik stressed early diagnosis, rapid treatment, and aggressive surveillance as the backbone of elimination efforts

Centre intensifies push for zero leprosy transmission

Health Ministry reviews progress, highlights targeted interventions in high-burden states, and calls for stronger surveillance and stigma reduction to achieve a leprosy-free India

Bayer’s asundexian moves into EU regulatory review as stroke prevention race intensifies

The validation confirms the submission is complete, clearing the way for the EMA’s centralized review process to formally evaluate the therapy

Health ministry classifies Pregabalin under Schedule H1 to curb misuse

New regulation mandates stricter prescription monitoring, sales record maintenance, and enhanced compliance across the pharmaceutical supply chain

Supriya Lifescience receives USFDA EIR with VAI classification for Maharashtra API facility

Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States

Granules Life Sciences receives VAI Classification for Shamirpet facility

The inspection is now closed, and no regulatory action has been recommended

APL Healthcare’s Unit-IV classified as VAI by the USFDA

This inspection is now closed

Biocon Biologics' Drug Substance Facility in Bengaluru cassified as VAI

This relates to the manufacture and supply of Human Recombinant Insulin (rh- Insulin) and Biosimilar Pegfilgrastim Drug Substance to the United States

FDA grants De Novo classification to first needle-free, glucose sensor Biolinq Shine

USFDA classifies Aurobindo Pharma Inc's warehouse as OAI

The USFDA has determined the inspection classification status of this warehousing facility as 'Official Action Indicated